USPTO serial 79375222
KIDNEY PYJAMAS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Nov 26, 2024
- Examiner
- AGREDA, SAMANTHA LEIGH
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with KIDNEY PYJAMAS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jennifer A. Visintine
Jennifer A. Visintine Thompson Coburn LLPOne US Bank PlazaSt. Louis, MO 63101United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Renal scanning agents for medical use being pharmaceutical preparations for use in ex-vivo and in-vivo diagnosis of kidney disorders; renal scanning agents for medical use being pharmaceutical preparations for use in in-vivo diagnosis of kidney disorders; in-vivo and ex-vivo diagnostic materials for medical use being pharmaceutical preparations for the diagnosis of kidney disorders; diagnostic testing materials for medical use being pharmaceutical preparations for use in the diagnosis of kidney disorders; in-vivo diagnostic materials for medical use being pharmaceutical preparations for use in the diagnosis of kidney disorders; in-vivo and ex-vivo diagnostic preparations for medical use being pharmaceutical preparations for use in the diagnosis of kidney disorders; diagnostic preparations for medical use in-vivo diagnosis being pharmaceutical preparations for use in the diagnosis of kidney disorders; in-vivo and ex-vivo radiodiagnostic agents for medical use being pharmaceutical preparations for use in the radiodiagnosis of kidney disorders; diagnostic scanning agents for in-vivo use being pharmaceutical preparations for use in the diagnosis of kidney disorders; in vivo medical diagnostic scanning agents for medical use being pharmaceutical preparations for use in the diagnosis of kidney disorders; pharmaceutical preparations for the preservation and storage of human organs between transplant surgeries; pharmaceutical preparations for the preservation and storage of human organs; solutions for medical use being pharmaceutical preparations for use in the preservation of organs between transplant surgeries; solutions for medical use being pharmaceutical preparations for use in the storage of organs between transplant surgeries | ACTIVE | — |
| 010 | medical supports for the body, namely, a medical sheath for the encasement of donor transplant organs during storage and transportation; medical supports for the body, namely, a medical sheath for the encasement of donor transplant organs during transplantation surgery; surgical apparatus for use in transplant surgery, namely, a medical sheath for the encasement of donor transplant organs during storage and transportation; surgical implants comprised of artificial materials; medical apparatus and instruments for the purposes of long-term graft survival during organ transplant surgery; medical apparatus and instruments for the purposes of short-term graft preservation during organ transplant surgery | ACTIVE | — |
| 042 | Research and development of technology in the field of maintenance, preservation, transportation and storage of organs in-vivo and ex-vivo; research and development of new products for others; scientific research to develop new products; scientific research into the development of new products; technical research into the development of new products; medical research services in relation to maintaining and improving the quality of organs in-vivo and ex-vivo; medical and pharmacological research services; medical research, namely, analysis of tissues for medical research; medical and scientific research, namely, conducting clinical trials for others; medical research; scientific research for medical purposes; pharmacological research not for medical purposes, namely, conducting pharmacological testing on organs and body parts in-vivo and ex-vivo; advisory services relating to pharmacology; consultancy pertaining to pharmacology; medical and scientific research, namely, conducting clinical trials for others; providing information about medical and scientific research in the field of pharmaceuticals, clinical trials and organ transplant surgeries; providing scientific research information and information about new product design, including online; scientific research consultancy in the field of pharmaceuticals, clinical trials and organ transplant surgeries; scientific research | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by IISHIELD PTY LTD
- Other trademarks owned by IISHIELD PTY LTD
- Other trademarks owned by IISHIELD PTY LTD
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Similar marks named KIDNEY PYJAMAS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 9, 2025 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Apr 22, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Apr 22, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Feb 26, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jan 10, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Dec 25, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Dec 25, 2024 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Nov 26, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Nov 26, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 24, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 24, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 4, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 19, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 17, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 17, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 17, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 15, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 15, 2024 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Jul 15, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 15, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jul 15, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jul 15, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Feb 6, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 18, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 18, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 30, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 29, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 26, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 15, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 11, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 10, 2023 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Jul 27, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |